<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IMR</journal-id>
<journal-id journal-id-type="hwp">spimr</journal-id>
<journal-title>Journal of International Medical Research</journal-title>
<issn pub-type="ppub">0300-0605</issn>
<issn pub-type="epub">1473-2300</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0300060513487631</article-id>
<article-id pub-id-type="publisher-id">10.1177_0300060513487631</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Notes</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The role of insulin-like growth factor 1 and its receptor in the formation and development of colorectal carcinoma</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Rong</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513487631">1</xref>
<xref ref-type="aff" rid="aff2-0300060513487631">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Xu</surname><given-names>Guo-Liang</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513487631">1</xref>
<xref ref-type="aff" rid="aff2-0300060513487631">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>Yin</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513487631">1</xref>
<xref ref-type="aff" rid="aff2-0300060513487631">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>He</surname><given-names>Long-Jun</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513487631">1</xref>
<xref ref-type="aff" rid="aff2-0300060513487631">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>Li-Ming</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513487631">1</xref>
<xref ref-type="aff" rid="aff2-0300060513487631">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Guo-Bao</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513487631">1</xref>
<xref ref-type="aff" rid="aff2-0300060513487631">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lin</surname><given-names>Shi-Yong</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513487631">1</xref>
<xref ref-type="aff" rid="aff2-0300060513487631">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Luo</surname><given-names>Guang-Yu</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513487631">1</xref>
<xref ref-type="aff" rid="aff2-0300060513487631">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gao</surname><given-names>Xiao-Yan</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513487631">1</xref>
<xref ref-type="aff" rid="aff2-0300060513487631">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Shan</surname><given-names>Hong-Bo</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513487631">1</xref>
<xref ref-type="aff" rid="aff2-0300060513487631">2</xref>
<xref ref-type="corresp" rid="corresp1-0300060513487631"/>
</contrib>
</contrib-group>
<aff id="aff1-0300060513487631"><label>1</label>State Key Laboratory of Oncology in Southern China, Guangzhou, China</aff>
<aff id="aff2-0300060513487631"><label>2</label>Department of Endoscopy, Sun Yat-sen University Cancer Centre, Guangzhou, China</aff>
<author-notes>
<corresp id="corresp1-0300060513487631">Dr Hong-Bo Shan, Department of Endoscopy, Sun Yat-sen University Cancer Centre, 651 Dongfeng Road East, Guangzhou 510060, China. Email: <email>drshanhongbo@yahoo.cn</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>41</volume>
<issue>4</issue>
<fpage>1228</fpage>
<lpage>1235</lpage>
<history>
<date date-type="received"><day>14</day><month>2</month><year>2013</year></date>
<date date-type="accepted"><day>28</day><month>2</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec15-0300060513487631"><title>Objective</title>
<p>To investigate the role of insulin-like growth factor (IGF)-1 and its receptor (IGF1R) in the formation and development of colorectal carcinoma.</p>
</sec>
<sec id="sec16-0300060513487631"><title>Methods</title>
<p>Colorectal tissue and matching serum samples were collected from patients with adenomatous polyps or carcinoma and healthy control subjects. IGF1R mRNA levels were determined via quantitative real-time reverse transcription–polymerase chain reaction. Serum IGF1 was quantified using enzyme-linked immunosorbent assay.</p>
</sec>
<sec id="sec17-0300060513487631"><title>Results</title>
<p>Serum IGF1 concentrations and mucosal IGF1R mRNA levels were significantly higher in patients with adenomatous polyps (<italic>n</italic> = 24) or carcinoma (<italic>n</italic> = 13) compared with healthy control subjects (<italic>n</italic> = 13). There was a significant positive correlation between serum IGF1 and mucosal IGF1R mRNA in patients with adenomatous polyps.</p>
</sec>
<sec id="sec18-0300060513487631"><title>Conclusions</title>
<p>High circulating IGF1 concentrations and mucosal IGF1R expression may play important roles in both the formation and development of colorectal carcinoma. IGF1 and its receptor may be activated before carcinogenesis, and may promote the growth and malignant transformation of adenomatous polyps. IGF1 and IGF1R may be useful biomarkers for evaluating the stage and risk of carcinogenesis.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Insulin-like growth factor 1</kwd>
<kwd>insulin-like growth factor receptor</kwd>
<kwd>colorectal polyps</kwd>
<kwd>colorectal carcinoma</kwd>
<kwd>quantitative real-time RT–PCR</kwd>
<kwd>enzyme-linked immunosorbent assay</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0300060513487631" sec-type="intro"><title>Introduction</title>
<p>The neoplastic initiation of colorectal cancer primarily begins with the formation of adenomatous polyps that can be detected by endoscopy.<sup><xref ref-type="bibr" rid="bibr1-0300060513487631">1</xref></sup> The morphological transition from normal colorectal mucosa to adenomatous polyps, early cancer and eventually to advanced cancer is widely accepted as the neoplastic progression of colorectal cancer. This process is facilitated by abnormal cell proliferation, differentiation and apoptosis.<sup><xref ref-type="bibr" rid="bibr2-0300060513487631">2</xref>,<xref ref-type="bibr" rid="bibr3-0300060513487631">3</xref></sup> In addition, multiple growth factors are believed to be involved in neoplastic progression.<sup><xref ref-type="bibr" rid="bibr4-0300060513487631">4</xref><xref ref-type="bibr" rid="bibr5-0300060513487631"/><xref ref-type="bibr" rid="bibr6-0300060513487631"/><xref ref-type="bibr" rid="bibr7-0300060513487631"/>–<xref ref-type="bibr" rid="bibr8-0300060513487631">8</xref></sup> Investigating changes in growth factors and their receptors may reveal the mechanisms of neoplastic initiation and identify new molecular targets for anticancer strategies.</p>
<p>The insulin-like growth factor type 1 receptor (IGF1R) signalling pathway is activated by IGF1.<sup><xref ref-type="bibr" rid="bibr9-0300060513487631">9</xref></sup> Growth hormone stimulates the production of IGF1 as an endocrine hormone, in addition to stimulation in a paracrine/autocrine manner;<sup><xref ref-type="bibr" rid="bibr10-0300060513487631">10</xref>,<xref ref-type="bibr" rid="bibr11-0300060513487631">11</xref></sup> IGF1 then activates the transmembrane IGFR and its downstream signalling pathway.<sup><xref ref-type="bibr" rid="bibr12-0300060513487631">12</xref>,<xref ref-type="bibr" rid="bibr13-0300060513487631">13</xref></sup> The IGF1/IGF1R system is highly conserved and is crucial in cell proliferation, differentiation and tissue development.<sup><xref ref-type="bibr" rid="bibr14-0300060513487631">14</xref><xref ref-type="bibr" rid="bibr15-0300060513487631"/><xref ref-type="bibr" rid="bibr16-0300060513487631"/>–<xref ref-type="bibr" rid="bibr17-0300060513487631">17</xref></sup> These functions have raised interest in the role of the IGF pathway in carcinogenesis, which is closely related to abnormal cell proliferation, differentiation, apoptosis and transformation.<sup><xref ref-type="bibr" rid="bibr18-0300060513487631">18</xref>,<xref ref-type="bibr" rid="bibr19-0300060513487631">19</xref></sup> Studies have linked IGF1 to human tumours, including colorectal cancer.<sup><xref ref-type="bibr" rid="bibr20-0300060513487631">20</xref></sup> IGF1 also has been shown to induce the transcription of vascular endothelial growth factor, resulting in colorectal cancer development, angiogenesis and metastasis.<sup><xref ref-type="bibr" rid="bibr21-0300060513487631">21</xref></sup> In addition, IGF1R was shown to be overexpressed in human colorectal tumours compared with normal colorectal tissue, resulting in enhanced tumour cell proliferation, malignant transformation and inhibition of apoptosis.<sup><xref ref-type="bibr" rid="bibr22-0300060513487631">22</xref>,<xref ref-type="bibr" rid="bibr23-0300060513487631">23</xref></sup> An overactive abnormal IGF1R β-subunit induced oncogenic transformation of IGF-1R knockout mouse fibroblasts <italic>in vitro</italic>, indicating that activated IGF1R may have an important role in the neoplastic process.<sup><xref ref-type="bibr" rid="bibr24-0300060513487631">24</xref>,<xref ref-type="bibr" rid="bibr25-0300060513487631">25</xref></sup></p>
<p>The effect of IGF1 and IGF1R on precancerous lesions (such as adenomatous polyps) has not been widely investigated: research has generally been limited to comparison with cancerous lesions. There are different pathological types of colorectal polyps, each with varying biological behaviour, morphological characteristics and malignant potential.<sup><xref ref-type="bibr" rid="bibr26-0300060513487631">26</xref><xref ref-type="bibr" rid="bibr27-0300060513487631"/>–<xref ref-type="bibr" rid="bibr28-0300060513487631">28</xref></sup> Adenomatous polyps, which possess a highly disordered structure and cell atypia (moderate to severe dysplasia), are more likely to develop into cancer than hyperplastic and inflammatory polyps.<sup><xref ref-type="bibr" rid="bibr29-0300060513487631">29</xref>,<xref ref-type="bibr" rid="bibr30-0300060513487631">30</xref></sup> Excessive cell proliferation caused by upregulation of IGF1/IGF1R greatly increases the probability of tumourigenesis,<sup><xref ref-type="bibr" rid="bibr24-0300060513487631">24</xref></sup> and the IGF1 pathway may therefore have an important role, not only in malignant tumours but also in tumour initiation in precancerous lesions such as colorectal adenomatous polyps.</p>
<p>The aim of the present study was to determine whether serum IGF1 concentrations (quantified by enzyme linked immunosorbent assay [ELISA]) and/or IGF1R mRNA expression (quantified via quantitative real-time reverse transcription–polymerase chain reaction [RT–PCR]) in colorectal tissue are related to the occurrence of colorectal adenomatous polyps or carcinoma. We also investigated whether IGF1 and its receptor could be used as biomarkers to evaluate the risk of colorectal carcinogenesis.</p>
</sec>
<sec id="sec2-0300060513487631" sec-type="methods"><title>Patients and methods</title>
<sec id="sec3-0300060513487631"><title>Study population</title>
<p>The study recruited patients undergoing surgical resection of colorectal adenocarcinoma or colonoscopy with polypectomy at the Sun Yat-sen University Cancer Centre, Guangzhou, China, between November 2009 and November 2010. The control group was recruited from individuals with symptoms including rectal bleeding, bloody stools, abdominal pain, constipation and diarrhoea who were attending the outpatient Clinic of Sun Yat-sen University Cancer Centre; these people subsequently had negative colonoscopy findings. Subjects with colitis, acromegaly, dwarfism, diabetes, cachexia, severe organ failure or other malignancies were excluded.</p>
<p>Blood (5 ml) was collected from each participant, then centrifuged at 1500 <bold><italic>g</italic></bold> at 15℃ for 10 min. All study participants provided colorectal tissue (adenocarcinoma, polyp or normal tissue, as applicable), which was pathologically examined and confirmed. Tissue and serum samples were stored at −80℃ until use.</p>
<p>The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Sun Yat-sen University Cancer Centre. Participants were informed of the investigational nature of the study and provided their written informed consent.</p>
</sec>
<sec id="sec4-0300060513487631"><title>IGF1R quantitative real-time RT–PCR</title>
<p>Tissue samples were frozen at −80℃ in RNAlater® (Qiagen, Valencia, CA, USA) immediately after collection. For RNA extraction, 20–50 mg of tissue was ground and incubated with 1 ml cell lysis buffer (Trizol®; Gibco, Gaithersburg, MD, USA) for 5 min and total RNA was isolated using the acid-guanidinium isothiocyanate phenol chloroform extraction method.<sup><xref ref-type="bibr" rid="bibr31-0300060513487631">31</xref></sup> RNA concentration and purity were determined by ultraviolet spectrophotometry, and RNA was stored at −80℃ for future analysis.</p>
<p>Total RNA (4 µl) was incubated for 60 min at 37℃ in a 20 µl reaction volume comprising RT buffer (50 mM Tris‐HCl [pH 8.0], 50 mM potassium chloride, 4 mM magnesium chloride, 10 mM dithiothreitol), 0.25 mM dNTPs, 4 pmol random primers, and 200 U MMLV reverse transcriptase. The reaction was stopped by incubation at 95℃ for 3 min; samples were then placed on ice.</p>
<p>Quantitative real‐time PCR was performed with a SYBR®green‐based ABI 7500 Real‐Time PCR system (Life Technologies, Grand Island, NY, USA). Primer sequences were: IGF1R forward 5′‐GCCAAGCTAAACCGGCTAAA‐3′ and reverse 5′‐TATCCTGTTTTGGCCTGGACATA-3′; and ACTB (β-actin) forward 5′-GCATGGGTCAGAAGGATTCCT-3′ and reverse 5′-TCGTCCCAGTTGGTGACGAT-3′. PCR was carried out in a 50-µl reaction volume comprising PCR buffer (10 mM Tris-HCl [pH 8.0], 50 mM potassium chloride, 2 mM magnesium chloride), 200 µM dNTPs, 0.2 pmol/µl each primer, and 0.06 U/µl Taq DNA polymerase. The cycling programme involved preliminary denaturation at 95℃ for 3 min, followed by 36 cycles of denaturation at 95℃ for 30 s, annealing at 58℃ for 30 s and elongation at 72℃ for 45 s, followed by a final elongation step at 72℃ for 7 min. The threshold cycle (<italic>C<sub>T</sub></italic>) was used to determine the concentration of the target gene, with ACTB used as an internal control, and the ratio of IGF1R to ACTB representing the transcription level of IGF1R.</p>
</sec>
<sec id="sec5-0300060513487631"><title>IGF1 ELISA</title>
<p>Serum IGF1 was quantified using a human IGF1 Quantikine® ELISA kit (R&amp;D Systems, Minneapolis, MN, USA), according to the manufacturer’s instructions. Optical density at 450 nm was determined using a microplate reader, with wavelength correction of 540 nm. All samples, standards and controls were assayed in duplicate, and IGF1 was quantified by reference to a standard curve.</p>
</sec>
<sec id="sec6-0300060513487631"><title>Statistical analyses</title>
<p>Data were presented as mean ± SD. Between-group differences in age and sex were analysed using one-way analysis of variance (ANOVA) and χ<sup>2</sup>-test, and one-way ANOVA with <italic>posthoc</italic> Bonferroni <italic>t</italic>-test was used for between-group comparisons of IGF1 and IGF1R levels. Spearman’s rank correlation analysis was used to determine the relationship between IGF1R mRNA levels and IGF1 concentration in patients with adenomatous polyps. All statistical analyses were performed with SPSS® software, version 17.0 (SPSS Inc., Chicago, IL, USA), and a <italic>P</italic>-value &lt;0.05 was considered to be statistically significant.</p>
</sec>
</sec>
<sec id="sec7-0300060513487631" sec-type="results"><title>Results</title>
<p>The study collected colorectal tissue samples from 24 patients undergoing colonoscopy and polypectomy (17 males/seven females; mean age 58.0 ± 13.9; age range 17–76 years), 13 patients undergoing surgical resection of colorectal adenocarcinoma (nine males/four females; mean age 49.7 ± 19. 8; age range 35–83 years) and 13 healthy control subjects (six males/seven females; mean age 57.0 ± 13.7; age range 22–82 years). There were no statistically significant between-group differences in age or sex distribution.</p>
<p><xref ref-type="table" rid="table1-0300060513487631">Table 1</xref> shows the tissue levels of IGF1R mRNA and serum IGF1 concentrations in the three study groups. Levels of IGF1R mRNA were significantly higher in adenomatous polyps and adenocarcinoma tissue compared with normal mucosa (<italic>P</italic> &lt; 0.01 for both comparisons; <xref ref-type="table" rid="table1-0300060513487631">Table 1</xref>). In addition, serum IGF1 concentrations were significantly higher in patients with adenomatous polyps or adenocarcinoma compared with healthy controls (<italic>P</italic> &lt; 0.01 for both comparisons; <xref ref-type="table" rid="table1-0300060513487631">Table 1</xref>). There were no significant differences between the adenomatous polyp group and adenocarcinoma group in IGF1R mRNA or IGF1 levels.
<table-wrap id="table1-0300060513487631" position="float"><label>Table 1.</label><caption><p>Serum insulin-like growth factor (IGF)-1 concentrations and IGF receptor 1 (IGF1R) mRNA levels in colorectal tissue samples from patients with colorectal adenomatous polyps or adenocarcinoma and healthy control subjects.</p></caption>
<graphic alternate-form-of="table1-0300060513487631" xlink:href="10.1177_0300060513487631-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Parameter</th>
<th>Adenomatous polyp group <italic>n</italic> = 24</th>
<th>Adenocarcinoma group <italic>n</italic> = 13</th>
<th>Control group <italic>n</italic> = 13</th>
</tr></thead>
<tbody align="left">
<tr>
<td>IGF1R mRNA<sup><xref ref-type="table-fn" rid="table-fn1-0300060513487631">a</xref></sup></td>
<td>2.63 ± 1.73<xref ref-type="table-fn" rid="table-fn2-0300060513487631">**</xref></td>
<td>3.23 ± 1.55<xref ref-type="table-fn" rid="table-fn2-0300060513487631">**</xref></td>
<td>0.43 ± 0.25</td>
</tr>
<tr>
<td>IGF1, ng/ml</td>
<td>200.96 ± 55.92<xref ref-type="table-fn" rid="table-fn2-0300060513487631">**</xref></td>
<td>218.77 ± 28.93<xref ref-type="table-fn" rid="table-fn2-0300060513487631">**</xref></td>
<td>98.37 ± 24.99</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0300060513487631"><p>Data presented as mean ± SD.</p></fn>
<fn id="table-fn2-0300060513487631"><label>a</label><p>Ratio of IGF1R to ACTB (β-actin) mRNA.</p></fn>
<fn id="table-fn3-0300060513487631"><label>**</label><p><italic>P</italic> &lt; 0.01 versus control group; one-way analysis of variance with <italic>posthoc</italic> Bonferroni <italic>t</italic>-test.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Spearman’s rank correlation analysis revealed a significant correlation between serum IGF1 concentration and IGF1R mRNA tissue levels in patients with adenomatous polyps (<italic>r</italic><sub>s</sub> = 0.552, <italic>P</italic> &lt; 0.01).</p>
</sec>
<sec id="sec8-0300060513487631" sec-type="discussion"><title>Discussion</title>
<p>Insulin-like growth factor 1 is known to be more important for the proliferation and growth of malignant cells <italic>in vitro</italic> than that of normal tissues,<sup><xref ref-type="bibr" rid="bibr32-0300060513487631">32</xref>,<xref ref-type="bibr" rid="bibr33-0300060513487631">33</xref></sup> and circulating IGF1 levels are known to be increased in patients with cancer.<sup><xref ref-type="bibr" rid="bibr20-0300060513487631">20</xref></sup> Serum IGF1 concentrations were significantly higher in patients with colorectal adenomatous polyps or adenocarcinoma than in healthy control subjects, in the present study. This suggests that high serum IGF1 concentrations may be important not only in malignant growth but also for benign precancerous growth. Cellular mutations accumulate with age and lead to apoptosis.<sup><xref ref-type="bibr" rid="bibr34-0300060513487631">34</xref><xref ref-type="bibr" rid="bibr35-0300060513487631"/>–<xref ref-type="bibr" rid="bibr36-0300060513487631">36</xref></sup> IGF1 can protect malignant cells from apoptosis,<sup><xref ref-type="bibr" rid="bibr24-0300060513487631">24</xref></sup> and continually high circulating IGF1 may allow malignant transformation of mutant epithelial cells.</p>
<p>An immunostaining study revealed that IGF1R levels were significantly higher in precancerous adenomatous polyps compared with normal mucosa, but remained low in inflammatory polyps.<sup><xref ref-type="bibr" rid="bibr37-0300060513487631">37</xref></sup> These data are in accordance with the findings of the present study, where IGF1R mRNA was found at a higher level in both colorectal adenomatous polyps and adenocarcinoma compared with normal tissue. The IGF1R signalling pathway may therefore be involved in the proliferation of abnormal colorectal epithelia as early as the precancerous adenomatous polyp stage. The present finding, that IGF1R is expressed at a high level in the adenoma stage, indicates that the abnormal epithelia in adenomatous polyps may develop the capability to utilize IGF1 from the surrounding environment more efficiently than normal colorectal epithelia. Since overexpression of IGF1R is found in colorectal adenocarcinoma,<sup><xref ref-type="bibr" rid="bibr22-0300060513487631">22</xref>,<xref ref-type="bibr" rid="bibr27-0300060513487631">27</xref></sup> the high level of IGF1R in adenomatous polyps suggests that both benign adenoma and malignant carcinoma cells utilize the same strategy to maintain rapid proliferation. Overexpression of <italic>IGF1R</italic> may be a molecular event associated with the precancerous transition of colorectal epithelial cells.</p>
<p>Pretreatment of A549 nonsmall cell lung cancer and Saos-2/B-10 osteoblastic osteosarcoma cell lines with IGF1 downregulated total and membrane surface-bound IGF1R and largely reduced the acute IGF1 response of cells <italic>in vitro</italic>.<sup><xref ref-type="bibr" rid="bibr38-0300060513487631">38</xref></sup> Findings of the present study suggest a different pattern for the feedback loop between IGF1R and its ligands <italic>in vivo</italic>, since high levels of both IGF1 and IGF1R were present in colorectal adenoma and carcinoma tissues. The present data suggest that both circulating IGF1 and IGF1R expression in adenoma and carcinoma tissues play important roles in the proliferation of abnormal precancerous and malignant cells. The significant correlation between serum IGF1 concentration and IGF1R mRNA levels in patients with adenomatous polyps in the present study suggests the existence of a positive feedback loop. The regulation of IGF1 and its receptor therefore requires further investigation.</p>
<p>An inhibitor of the tyrosine kinase activity of IGF1R, NVP-AEW541 has been shown to inhibit proliferation of colorectal carcinoma cell lines and primary cell cultures by inducing apoptosis and cell-cycle arrest, and may represent a promising anticancer treatment for colorectal carcinoma.<sup><xref ref-type="bibr" rid="bibr39-0300060513487631">39</xref></sup> The present findings suggest that high circulating IGF1 concentrations and IGF1R overexpression may play important roles in the development of both adenomatous polyps and colorectal carcinoma. Inhibition of IGF1R, reducing serum IGF1 concentrations or blocking IGF1/IGF1R binding may all be potential chemopreventive measures for colorectal cancer.</p>
<p>Because colorectal adenomatous polyps commonly develop into colorectal cancer, screening programs that rely on colonoscopies to detect and remove polyps have been shown to be effective in reducing the morbidity and mortality of colon cancer.<sup><xref ref-type="bibr" rid="bibr40-0300060513487631">40</xref></sup> Colonoscopies are not widely accepted, however, due to poor compliance and heightened risk of complications.<sup><xref ref-type="bibr" rid="bibr41-0300060513487631">41</xref></sup> Serum IGF1 concentrations and mucosal IGF1R mRNA levels may be useful biomarkers for evaluating the stage and risk of carcinogenesis during neoplastic initiation and colorectal cancer progression.</p>
<p>In conclusion, the present study found high serum IGF1 concentrations and IGF1R mRNA levels in adenomatous polyps and adenocarcinoma tissue compared with normal mucosa, suggesting that IGF1 and IGF1R are activated before carcinogenesis, and may play important roles in malignant transformation. Serum IGF1 concentrations and mucosal IGF1R mRNA levels may be useful in indicating the risk of adenomatous polyp formation or colorectal cancer progression. Further studies regarding regulation of the IGF1/IGF1R axis and <italic>IGF1R</italic> expression are required to elucidate the role of this signalling pathway in the initiation and progression of colorectal cancer.</p>
</sec>
</body>
<back><ack><title>Acknowledgements</title>
<p>We thank Dr Dong-Ping Rao (Department of Epidemiology, State Key Laboratory of Oncology in Southern China, Guangzhou, China) for assistance with statistical analyses.</p></ack>
<sec id="sec13-0300060513487631"><title>Declaration of conflicting interest</title>
<p>The authors declare that there are no conflicts of interest.</p>
</sec>
<sec id="sec14-0300060513487631"><title>Funding</title>
<p>This study was supported by Science and Technology Planning Project of Guangdong Province 2009B030801158, 2012B031800097, 2012B031800282.</p>
</sec>
<ref-list><title>References</title>
<ref id="bibr1-0300060513487631"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S</given-names></name></person-group>. <article-title>Colorectal polyps: the scope and management of the problem</article-title>. <source>Am J Med Sci</source> <year>2008</year>; <volume>336</volume>: <fpage>407</fpage>–<lpage>417</lpage>.</citation></ref>
<ref id="bibr2-0300060513487631"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jass</surname><given-names>JR</given-names></name><name><surname>Young</surname><given-names>J</given-names></name><name><surname>Leggett</surname><given-names>BA</given-names></name></person-group>. <article-title>Evolution of colorectal cancer: change of pace and change of direction</article-title>. <source>J Gastroenterol Hepatol</source> <year>2002</year>; <volume>17</volume>: <fpage>17</fpage>–<lpage>26</lpage>.</citation></ref>
<ref id="bibr3-0300060513487631"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahlquist</surname><given-names>DA</given-names></name></person-group>. <article-title>Molecular detection of colorectal neoplasia</article-title>. <source>Gastroenterology</source> <year>2010</year>; <volume>138</volume>: <fpage>2127</fpage>–<lpage>2139</lpage>.</citation></ref>
<ref id="bibr4-0300060513487631"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kucera</surname><given-names>R</given-names></name><name><surname>Cerna</surname><given-names>M</given-names></name><name><surname>Narsanska</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Growth factors and breast tumors, comparison of selected growth factors with traditional tumor markers</article-title>. <source>Anticancer Res</source> <year>2011</year>; <volume>31</volume>: <fpage>4653</fpage>–<lpage>4656</lpage>.</citation></ref>
<ref id="bibr5-0300060513487631"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCarty</surname><given-names>G</given-names></name><name><surname>Awad</surname><given-names>O</given-names></name><name><surname>Loeb</surname><given-names>DM</given-names></name></person-group>. <article-title>WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia</article-title>. <source>J Biol Chem</source> <year>2011</year>; <volume>286</volume>: <fpage>43634</fpage>–<lpage>43643</lpage>.</citation></ref>
<ref id="bibr6-0300060513487631"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kasprzak</surname><given-names>A</given-names></name><name><surname>Adamek</surname><given-names>A</given-names></name></person-group>. <article-title>The insulin-like growth factor (IGF) signaling axis and hepatitis C virus-associated carcinogenesis (review)</article-title>. <source>Int J Oncol</source> <year>2012</year>; <volume>41</volume>: <fpage>1919</fpage>–<lpage>1931</lpage>.</citation></ref>
<ref id="bibr7-0300060513487631"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rapisarda</surname><given-names>A</given-names></name><name><surname>Melillo</surname><given-names>G</given-names></name></person-group>. <article-title>Role of the VEGF/VEGFR axis in cancer biology and therapy</article-title>. <source>Adv Cancer Res</source> <year>2012</year>; <volume>114</volume>: <fpage>237</fpage>–<lpage>267</lpage>.</citation></ref>
<ref id="bibr8-0300060513487631"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ozkan</surname><given-names>EE</given-names></name></person-group>. <article-title>Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review</article-title>. <source>Mol Cell Endocrinol</source> <year>2011</year>; <volume>344</volume>: <fpage>1</fpage>–<lpage>24</lpage>.</citation></ref>
<ref id="bibr9-0300060513487631"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dupont</surname><given-names>J</given-names></name><name><surname>Pierre</surname><given-names>A</given-names></name><name><surname>Froment</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>The insulin-like growth factor axis in cell cycle progression</article-title>. <source>Horm Metab Res</source> <year>2003</year>; <volume>35</volume>: <fpage>740</fpage>–<lpage>750</lpage>.</citation></ref>
<ref id="bibr10-0300060513487631"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woelfle</surname><given-names>J</given-names></name><name><surname>Billiard</surname><given-names>J</given-names></name><name><surname>Rotwein</surname><given-names>P</given-names></name></person-group>. <article-title>Acute control of insulin-like growth factor-I gene transcription by growth hormone through Stat5b</article-title>. <source>J Biol Chem</source> <year>2003</year>; <volume>278</volume>: <fpage>22696</fpage>–<lpage>22702</lpage>.</citation></ref>
<ref id="bibr11-0300060513487631"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chesik</surname><given-names>D</given-names></name><name><surname>Glazenburg</surname><given-names>K</given-names></name><name><surname>Wilczak</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Insulin-like growth factor binding protein-1-6 expression in activated microglia</article-title>. <source>Neuroreport</source> <year>2004</year>; <volume>15</volume>: <fpage>1033</fpage>–<lpage>1037</lpage>.</citation></ref>
<ref id="bibr12-0300060513487631"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>C</given-names></name></person-group>. <article-title>The chemotactic and mitogenic responses of vascular smooth muscle cells to insulin-like growth factor-I require the activation of ERK1/2</article-title>. <source>Mol Cell Endocrinol</source> <year>2003</year>; <volume>206</volume>: <fpage>75</fpage>–<lpage>83</lpage>.</citation></ref>
<ref id="bibr13-0300060513487631"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>B</given-names></name><name><surname>van Golen</surname><given-names>CM</given-names></name><name><surname>Feldman</surname><given-names>EL</given-names></name></person-group>. <article-title>Insulin-like growth factor-I signaling in human neuroblastoma cells</article-title>. <source>Oncogene</source> <year>2004</year>; <volume>23</volume>: <fpage>130</fpage>–<lpage>141</lpage>.</citation></ref>
<ref id="bibr14-0300060513487631"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ikeo</surname><given-names>S</given-names></name><name><surname>Yamauchi</surname><given-names>K</given-names></name><name><surname>Shigematsu</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Differential effects of growth hormone and insulin-like growth factor I on human endothelial cell migration</article-title>. <source>Am J Physiol Cell Physiol</source> <year>2001</year>; <volume>280</volume>: <fpage>C1255</fpage>–<lpage>1261</lpage>.</citation></ref>
<ref id="bibr15-0300060513487631"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qiang</surname><given-names>YW</given-names></name><name><surname>Kopantzev</surname><given-names>E</given-names></name><name><surname>Rudikoff</surname><given-names>S</given-names></name></person-group>. <article-title>Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk</article-title>. <source>Blood</source> <year>2002</year>; <volume>99</volume>: <fpage>4138</fpage>–<lpage>4146</lpage>.</citation></ref>
<ref id="bibr16-0300060513487631"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Del Valle</surname><given-names>L</given-names></name><name><surname>Enam</surname><given-names>S</given-names></name><name><surname>Lassak</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Insulin-like growth factor I receptor activity in human medulloblastomas</article-title>. <source>Clin Cancer Res</source> <year>2002</year>; <volume>8</volume>: <fpage>1822</fpage>–<lpage>1830</lpage>.</citation></ref>
<ref id="bibr17-0300060513487631"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saikali</surname><given-names>Z</given-names></name><name><surname>Setya</surname><given-names>H</given-names></name><name><surname>Singh</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Role of IGF-1/IGF-1R in regulation of invasion in DU145 prostate cancer cells</article-title>. <source>Cancer Cell Int</source> <year>2008</year>; <volume>8</volume>: <fpage>10</fpage>–<lpage>10</lpage>.</citation></ref>
<ref id="bibr18-0300060513487631"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>YH</given-names></name><name><surname>Yee</surname><given-names>D</given-names></name></person-group>. <article-title>Insulin-like growth factor-I and cancer risk</article-title>. <source>Growth Horm IGF Res</source> <year>2004</year>; <volume>14</volume>: <fpage>261</fpage>–<lpage>269</lpage>.</citation></ref>
<ref id="bibr19-0300060513487631"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hartog</surname><given-names>H</given-names></name><name><surname>Wesseling</surname><given-names>J</given-names></name><name><surname>Boezen</surname><given-names>HM</given-names></name><etal/></person-group>. <article-title>The insulin-like growth factor 1 receptor in cancer: old focus, new future</article-title>. <source>Eur J Cancer</source> <year>2007</year>; <volume>43</volume>: <fpage>1895</fpage>–<lpage>1904</lpage>.</citation></ref>
<ref id="bibr20-0300060513487631"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Yakar</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis</article-title>. <source>Cancer Res</source> <year>2002</year>; <volume>62</volume>: <fpage>1030</fpage>–<lpage>1035</lpage>.</citation></ref>
<ref id="bibr21-0300060513487631"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>R</given-names></name><name><surname>Hirota</surname><given-names>K</given-names></name><name><surname>Fan</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells</article-title>. <source>J Biol Chem</source> <year>2002</year>; <volume>277</volume>: <fpage>38205</fpage>–<lpage>38211</lpage>.</citation></ref>
<ref id="bibr22-0300060513487631"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>MM</given-names></name><name><surname>Fottner</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>SB</given-names></name><etal/></person-group>. <article-title>Overexpression of the insulin-like growth factor I receptor in human colon carcinomas</article-title>. <source>Cancer</source> <year>2002</year>; <volume>95</volume>: <fpage>2086</fpage>–<lpage>2095</lpage>.</citation></ref>
<ref id="bibr23-0300060513487631"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ouban</surname><given-names>A</given-names></name><name><surname>Muraca</surname><given-names>P</given-names></name><name><surname>Yeatman</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas</article-title>. <source>Hum Pathol</source> <year>2003</year>; <volume>34</volume>: <fpage>803</fpage>–<lpage>808</lpage>.</citation></ref>
<ref id="bibr24-0300060513487631"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Remacle-Bonnet</surname><given-names>MM</given-names></name><name><surname>Garrouste</surname><given-names>FL</given-names></name><name><surname>Heller</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways</article-title>. <source>Cancer Res</source> <year>2000</year>; <volume>60</volume>: <fpage>2007</fpage>–<lpage>2017</lpage>.</citation></ref>
<ref id="bibr25-0300060513487631"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Natalishvili</surname><given-names>N</given-names></name><name><surname>Axelson</surname><given-names>M</given-names></name><name><surname>Girnita</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Aberrant intracellular IGF-1R beta-subunit makes receptor knockout cells (IGF1R-/-) susceptible to oncogenic transformation</article-title>. <source>Exp Cell Res</source> <year>2009</year>; <volume>315</volume>: <fpage>1458</fpage>–<lpage>1467</lpage>.</citation></ref>
<ref id="bibr26-0300060513487631"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vrieling</surname><given-names>A</given-names></name><name><surname>Voskuil</surname><given-names>DW</given-names></name><name><surname>Bosma</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Expression of insulin-like growth factor system components in colorectal tissue and its relation with serum IGF levels</article-title>. <source>Growth Horm IGF Res</source> <year>2009</year>; <volume>19</volume>: <fpage>126</fpage>–<lpage>135</lpage>.</citation></ref>
<ref id="bibr27-0300060513487631"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hakam</surname><given-names>A</given-names></name><name><surname>Yeatman</surname><given-names>TJ</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Expression of insulin-like growth factor-1 receptor in human colorectal cancer</article-title>. <source>Hum Pathol</source> <year>1999</year>; <volume>30</volume>: <fpage>1128</fpage>–<lpage>1133</lpage>.</citation></ref>
<ref id="bibr28-0300060513487631"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nosho</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Taniguchi</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis</article-title>. <source>Clin Cancer Res</source> <year>2004</year>; <volume>10</volume>: <fpage>7950</fpage>–<lpage>7957</lpage>.</citation></ref>
<ref id="bibr29-0300060513487631"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>A</given-names></name><name><surname>Thun</surname><given-names>MJ</given-names></name><name><surname>Connell</surname><given-names>CJ</given-names></name><etal/></person-group>. <article-title>Meat consumption and risk of colorectal cancer</article-title>. <source>JAMA</source> <year>2005</year>; <volume>293</volume>: <fpage>172</fpage>–<lpage>182</lpage>.</citation></ref>
<ref id="bibr30-0300060513487631"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>HS</given-names></name></person-group>. <article-title>Pathologic issues in the treatment of endoscopically removed malignant colorectal polyps</article-title>. <source>J Natl Compr Canc Netw</source> <year>2007</year>; <volume>5</volume>: <fpage>991</fpage>–<lpage>996</lpage>.</citation></ref>
<ref id="bibr31-0300060513487631"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chomczynski</surname><given-names>P</given-names></name><name><surname>Sacchi</surname><given-names>N</given-names></name></person-group>. <article-title>Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction</article-title>. <source>Anal Biochem</source> <year>1987</year>; <volume>162</volume>: <fpage>156</fpage>–<lpage>159</lpage>.</citation></ref>
<ref id="bibr32-0300060513487631"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khatib</surname><given-names>AM</given-names></name><name><surname>Siegfried</surname><given-names>G</given-names></name><name><surname>Prat</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions</article-title>. <source>J Biol Chem</source> <year>2001</year>; <volume>276</volume>: <fpage>30686</fpage>–<lpage>30693</lpage>.</citation></ref>
<ref id="bibr33-0300060513487631"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>PJ</given-names></name><name><surname>Khalaf</surname><given-names>S</given-names></name><name><surname>Ogunkolade</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Differential expression of IGF-binding protein-3 in normal and malignant colon and its influence on apoptosis</article-title>. <source>Endocr Relat Cancer</source> <year>2005</year>; <volume>12</volume>: <fpage>891</fpage>–<lpage>901</lpage>.</citation></ref>
<ref id="bibr34-0300060513487631"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Best</surname><given-names>BP</given-names></name></person-group>. <article-title>Nuclear DNA damage as a direct cause of aging</article-title>. <source>Rejuvenation Res</source> <year>2009</year>; <volume>12</volume>: <fpage>199</fpage>–<lpage>208</lpage>.</citation></ref>
<ref id="bibr35-0300060513487631"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maslov</surname><given-names>AY</given-names></name><name><surname>Vijg</surname><given-names>J</given-names></name></person-group>. <article-title>Genome instability, cancer and aging</article-title>. <source>Biochim Biophys Acta</source> <year>2009</year>; <volume>1790</volume>: <fpage>963</fpage>–<lpage>969</lpage>.</citation></ref>
<ref id="bibr36-0300060513487631"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rupnarain</surname><given-names>C</given-names></name><name><surname>Dlamini</surname><given-names>Z</given-names></name><name><surname>Naicker</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Colon cancer: genomics and apoptotic events</article-title>. <source>Biol Chem</source> <year>2004</year>; <volume>385</volume>: <fpage>449</fpage>–<lpage>464</lpage>.</citation></ref>
<ref id="bibr37-0300060513487631"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>HB</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Expression of IGF-1R in colorectal polyps and its role in colorectal carcinogenesis</article-title>. <source>Technol Cancer Res Treat</source> <year>2011</year>; <volume>10</volume>: <fpage>381</fpage>–<lpage>389</lpage>.</citation></ref>
<ref id="bibr38-0300060513487631"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bostedt</surname><given-names>KT</given-names></name><name><surname>Schmid</surname><given-names>C</given-names></name><name><surname>Ghirlanda-Keller</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Insulin-like growth factor (IGF) I down-regulates type 1 IGF receptor (IGF 1R) and reduces the IGF I response in A549 non-small-cell lung cancer and Saos-2/B-10 osteoblastic osteosarcoma cells</article-title>. <source>Exp Cell Res</source> <year>2001</year>; <volume>271</volume>: <fpage>368</fpage>–<lpage>377</lpage>.</citation></ref>
<ref id="bibr39-0300060513487631"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hopfner</surname><given-names>M</given-names></name><name><surname>Sutter</surname><given-names>AP</given-names></name><name><surname>Huether</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer</article-title>. <source>World J Gastroenterol</source> <year>2006</year>; <volume>12</volume>: <fpage>5635</fpage>–<lpage>5643</lpage>.</citation></ref>
<ref id="bibr40-0300060513487631"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>GS</given-names></name><name><surname>Doug Kou</surname><given-names>T</given-names></name></person-group>. <article-title>Underuse of colorectal cancer screening in a cohort of Medicare beneficiaries</article-title>. <source>Cancer</source> <year>2008</year>; <volume>112</volume>: <fpage>293</fpage>–<lpage>299</lpage>.</citation></ref>
<ref id="bibr41-0300060513487631"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baxter</surname><given-names>N</given-names></name><name><surname>Rabeneck</surname><given-names>L</given-names></name></person-group>. <article-title>New findings about the risks and limitations of colonoscopy used in the early detection of colorectal cancer</article-title>. <source>Healthc Q</source> <year>2009</year>; <volume>12</volume>: <fpage>24</fpage>–<lpage>25</lpage>.</citation></ref>
</ref-list>
</back>
</article>